Health
Shorter Duration of Adjuvant Trastuzumab Shows Long-Term Survival Benefit in Select HER2+ Early Breast Cancer – OncLive
Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be…
Updated survival data from the phase 3 Short-HER trial (NCT00629278) presented during the ESMO Breast Cancer Virtual Congress 2021confirm the promising long-term results obtained with 9 weeks of adjuvant trastuzumab (Herceptin) in patients with HER2-positive early breast cancer who have low and intermediate risk factors, a population that is representative of most patients seen in clinical practice.1After a median follow-up of 8.7 years, patients who received 1 year of trastuzumab had a 5-year disease-free…
-
Noosa News12 hours agoTeenage girl dies in hit-and-run, police hunt for ute
-
Noosa News13 hours agoTeenage girl killed in alleged hit-and-run at Margate north of Brisbane
-
Noosa News7 hours agoArnie the dog found dead in stolen ute after week of searching
-
Noosa News7 hours ago‘Beyond devastated’ Brisbane family learn missing German shepherd Arnie found dead in back of stolen car